Site Spacer

BREVI-BATCH® Processing Platform

UPM Pharmaceuticals BREVI-BATCH Services Glatt MiniBREVI-BATCH® is a UPM trademark processing platform used for solid dose mini-scale R&D formulation development batches. BREVI-BATCH® is ideal for clients seeking to produce low-cost, high quality proof-of-concept results that will conserve valuable R&D API.

Using the mini-scale processing equipment, the BREVI-BATCH® target batch size is 100 – 500 grams, a scale significantly smaller than most small scale R&D formulation batches. The specialized equipment is designed for fast set-up and clean-up, and depending on the API toxicity, all processing can be done under containment conditions.

BREVI-BATCH® Equipment Highlights:

Quadro Comill U5

UPM Pharmaceuticals roller compactor equipment

  • 40g sample size
  • Over 200 different screens and dozens of impellers

Caleva Screen Extruder

  • Screen from 0.5-2.5mm
  • Processing rates or up to 20 kg per hour

Caleva MBS Spheronizer 120

  • Working capacity from 10 to 150 g
  • For limited or expensive material

L1A Fitzmill

  • Process as little as 5g with minimal loss
  • Process wet or dry products

Vector Freund TFC-Lab Micro Roller Compactor

  • Minimum sample size of 5 g
  • Up to 1kg per hour working capacity

Mini Glatt

  • Top Spray 50-750 ml
  • Bottom Spray 150-600ml
  • Standard container for 50-350 g and MicroKit for 2.5-50 g

Diosna P 1-6 High Shear Lab Mixer

  • 0.25, 0.5, 1, 2, 4, 6 liter stainless steel vessels
  • Reproducible mixing and granulating

PK Blendmaster V-Blender

  • 0.5, 1, and 2 shell sizes (quart)
  • 24 rpm Blender speed

Vector Freund LCDS Hi-Coater

  • 0.5, 1.5, 2.5, 4, 6, and 8 liter pan sizes
  • 34-100 m3 per hour at 25 – 100°C
  • Spray gun rate 5-30 ml per minute

M&O Perry Accodil Model FC

  • Fills from 2mg to 250 g

UPM views BREVI-BATCH® as essential to our clients, specifically those attempting to make the best and most cost effective decisions about the investment of precious research funds. By utilizing the UPM processing platform, organizations are able to make smaller research commitments earlier in the process.






All works © UPM Pharmaceuticals 2014